Johnson & Johnson
JNJEquityAI Summary
Updated 13h ago
Johnson & Johnson (JNJ) has lost significant upward energy
Johnson & Johnson (JNJ) has lost significant upward energy. Momentum indicators are at historically low levels across multiple timeframes — sellers have had the upper hand recently. For reference: Flow Score 24/100, Trend & Momentum Score 24/100.
Market Positioning
What's Happening
JNJ reports Q1 2026 earnings with 9.9% sales growth
Johnson & Johnson posted Q1 2026 revenue of $24.1 billion, up 9.9% reported, driven by double-digit growth in Innovative Medicine from oncology stars like DARZALEX and CARVYKTI, plus MedTech expansion. Net earnings fell to $5.2 billion due to prior-year talc reserve reversals not repeating—most miss how this sets up easier comps ahead. Company guidance raised full-year outlook signaling confidence in pipeline momentum.
The Bigger Picture
Healthcare giants navigate innovation and regulatory waves
Pipeline firepower drives sector leadership
JNJ's Q1 approvals for ICOTYDE and VARIPULSE Pro highlight unmatched R&D depth—over 75% of sales from #1 or #2 positions. Oncology like DARZALEX fuels 9.9% growth, positioning against Eli Lilly in a $200B+ market. Consensus estimates see EPS at $11.07 next year, up 4.63%.
Upcoming Catalysts
Updated 6d agoGovernance votes on board and comp; signals on capital allocation like buybacks from $2.5B Q1 cash flow. Dividend hike likely after 60+ year streak.
Post-Q1 raise sets high bar—watch oncology sales trajectory and updated guidance from Innovative Medicine. Talc comps ease further; beats could affirm pipeline bets.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for Johnson & Johnson (JNJ): extension is below average (15th percentile), momentum is deeply below average — at historically low levels (11th percentile), flow is slightly below average (40th percentile), volatility is slightly above average (57th percentile). The key to watch is whether flow stabilises above the 40th percentile while extension remains compressed. That combination would represent a historically more significant setup.
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
Johnson & Johnson (JNJ) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. If extension drops further into the lower teens while flow holds above the 40th percentile, that would represent a historically more significant setup. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required